BRIEF—New data to support label updates for Lokelma

AstraZeneca has presented positive results from the Phase IIIb DIALIZE trial of Lokelma (sodium zirconium cyclosilicate) in people with end-stage renal disease (ESRD) on hemodialysis.

Published in the Journal of the American Society of Nephrology, the results show a statistically-significant and clinically-meaningful improvement in the treatment of hyperkalemia.

Senior vice president Elisabeth Björk said: “These positive results show that Lokelma can normalize potassium levels in between dialysis sessions for patients with hyperkalaemia who have end-stage renal disease. There is a high unmet treatment need that affects a large patient population and we believe Lokelma can play a critical role.”

The therapy is approved and available in the USA and EU for the treatment of adults with hyperkalemia. Data from the trial will support label updates, as the dosing regimen used in the trial is not currently approved.